Novartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia

  • Foundation for Biomedical Research and Innovation (FBRI) in Kobe, Japan becomes first CAR-T cell therapy commercial manufacturing site in Asia
     
  • Novartis global CAR-T manufacturing footprint now spans four continents, bringing Kymriah closer to patients and healthcare professionals around the world
     
  • Prestigious FBRI is recognized for its world-class expertise and established practice in CAR-T cell therapy
     
  • Global CAR-T manufacturing growth includes recent FDA approval for further capacity expansion in the US, …
/by

Novartis presents latest Phase III data reinforcing Cosentyx® as a first-line systemic treatment in pediatric psoriasis

  • Latest data show Cosentyx® provides fast and strong skin clearance, significant improvement in quality of life and a favorable safety profile1,2
     
  • Moderate-to-severe psoriasis affects more than 350,000 children worldwide3, with the physical and psychological burden disrupting important formative years4
     
  • FDA has accepted a submission for Cosentyx in moderate-to-severe plaque psoriasis in children and adolescents aged 6 to <18 years
     
  • Cosentyx is backed …
/by

Novartis acquires Vedere Bio, adding novel optogenetic gene therapy technology for treating blindness

  • Acquisition expands the Novartis footprint in ophthalmology and enhances the company’s position as an AAV-based gene therapy powerhouse.

  • Novartis gains two pre-clinical optogenetic AAV gene therapy programs and novel delivery technology for treating inherited retinal dystrophies and geographic atrophy.

  • Inherited retinal dystrophies, including advanced retinitis pigmentosa, affect greater than 2 million patients worldwide, and geographic atrophy affects approximately 5 million patients worldwide.

…

/by

Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19

  • Novartis has been granted an option to in-license global rights of MP0420 and MP0423 – multi-targeted direct acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19
  • MP0420 and MP0423 are potential medicines with a unique approach for both the prevention and treatment of COVID-19, with the possibility to manufacture at scale, easy administration and with the potential to bypass cold storage
  • Switzerland based Molecular Partners, a global leader in the development of DARPin …
/by

Novartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance.

  • Q3 net sales from continuing operations1were in line with prior year (cc2, +1% USD):
    • Growth drivers included Entresto USD 632 million (+45% cc), Zolgensma USD 291 million (+79% cc), Cosentyx USD 1 012 million (+7% cc), Kisqali USD 183 million (+50% cc) and Promacta/Revolade USD 442 million (+16% cc)
    • Sandoz …
/by

Novartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G)

  • C3 glomerulopathy (C3G) is a rare renal disease, affecting young patients with a poor prognosis and significant unmet need.1–3 
  • Iptacopan (LNP023) is a potential first-in-class, oral, potent and selective factor B inhibitor of the complement system’s alternative pathway, targeting the underlying cause of C3G.4–6
  • Data presented at the American Society of Nephrology (ASN) 2020 Annual Meeting shows that investigational iptacopan …
/by

Novartis announces European Medicines Agency (EMA) has granted orphan drug designation for iptacopan (LNP023) in IgA nephropathy (IgAN)

  • Orphan drug designation is reserved for medicines treating rare, life-threatening or chronically debilitating diseases
  • IgA nephropathy (IgAN), while rare, is the most common form of glomerulonephritis, affecting mostly young adults with no approved treatment option and significant risk to progress to e …
/by

Novartis announces European Medicines Agency (EMA) has granted orphan drug designation for iptacopan (LNP023) in IgA nephropathy (IgAN)

  • Orphan drug designation is reserved for medicines treating rare, life-threatening or chronically debilitating diseases
  • IgA nephropathy (IgAN), while rare, is the most common form of glomerulonephritis, affecting mostly young adults with no approved treatment option and significant risk to progress to e …
/by

Novartis announces European Medicines Agency (EMA) has granted orphan drug designation for iptacopan (LNP023) in IgA nephropathy (IgAN)

  • Orphan drug designation is reserved for medicines treating rare, life-threatening or chronically debilitating diseases
  • IgA nephropathy (IgAN), while rare, is the most common form of glomerulonephritis, affecting mostly young adults with no approved treatment option and significant risk to progress to e …
/by